Saturday 17 October 2026
Export DNA’s income statement to Excel — free account
Ginkgo Bioworks Holdings, Inc.
In the quarter to June 2026, revenue fell 48.5%, EPS grew 31.8% and free cash flow fell 16.4%, each against the same quarter a year earlier.
10.27
1.49
−12.67%
Follow DNA
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 3 | 4 | 5 | 3 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 10.07 | (2.38) | (1.94) | (6.22) | (7.61) |
P/S ratio |
— | 0.00 | 0.00 | 36.01 | 5.55 | 12.91 | 2.24 | 2.71 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | 2.22 | (1.25) | (5.92) | (8.52) | (13.05) | (16.72) |
P/Operating CF |
— | (271.29) | (271.29) | (68.26) | (25.38) | (56.15) | (12.01) | (9.67) |
Beneish M-Score |
— | — | — | (3.50) | (5.05) | (5.42) | (2.72) | (2.80) |
P/B ratio |
— | 2,611.53 | 2,611.53 | 7.21 | 1.53 | 2.96 | 0.71 | 0.91 |
Price to Tangible BV |
— | 0.00 | 0.00 | 7.41 | 1.70 | 3.36 | 0.79 | 1.01 |
EV/Sales |
— | 0.00 | 0.00 | 31.14 | 2.92 | 9.40 | 0.03 | 0.58 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (140.87) | (140.87) | (38.50) | (5.54) | (8.00) | (0.02) | (0.57) |
EV/FCF |
— | (95.45) | (95.45) | (31.49) | (4.59) | (7.12) | (0.02) | (0.55) |
Quick Ratio |
— | — | 5.50 | 12.51 | 8.08 | 5.87 | 5.44 | 4.66 |
Current Ratio |
— | — | 5.83 | 12.79 | 8.38 | 6.11 | 5.62 | 4.92 |
Net Debt/EBITDA |
— | 0.00 | 2.96 | 0.85 | 0.61 | 1.19 | 1.25 | 1.63 |
Debt/Assets |
0.00% | 0.00% | 2.45% | 1.08% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.04 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.23 | 0.23 | 0.21 | 0.12 | 0.15 | 0.14 |
Operating CF/Net income |
— | 0.37 | 1.07 | 0.14 | 0.12 | 0.33 | 0.58 | 0.55 |
Capex/Depreciation |
— | (2.07) | (4.17) | (1.94) | (1.23) | (0.52) | (0.56) | (0.13) |
Interest Coverage |
— | (29.57) | (57.45) | (770.53) | (20,839.17) | (9,294.69) | (5,954.86) | — |
| — | 0.00% | (12.88%) | (179.64%) | (127.43%) | (63.02%) | (60.34%) | (51.08%) | |
| — | 0.00% | (37.51%) | (133.28%) | (91.31%) | (42.47%) | (35.96%) | (25.05%) | |
ROIC |
— | 0.00% | (80.97%) | (2,881.62%) | (328.33%) | (352.92%) | (226.46%) | (229.21%) |
Return on Tangible Assets |
— | 0.00% | (26.67%) | (105.54%) | (132.23%) | (87.02%) | (78.24%) | (57.53%) |
Average Days of Receivables |
— | 0.00 | 104.30 | 158.34 | 63.01 | 25.98 | 36.08 | 52.03 |
Research and Development Expense of Revenue |
— | 177.73% | 208.42% | 366.32% | 220.35% | 230.90% | 186.78% | 143.27% |
Selling, General and Administrative Expense of Revenue |
— | 54.41% | 49.97% | 274.97% | 299.31% | 153.12% | 108.42% | 107.72% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.02 | 0.07 | 0.08 | 0.05 | 0.05 |
Share Based Compensation of Revenue |
— | 1.42% | 0.62% | 511.74% | 404.15% | 91.42% | 49.48% | 47.92% |
Graham Net Nets |
— | (0.13) | (0.13) | 0.11 | 0.24 | 0.13 | (0.12) | (0.30) |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (1.73%) | (1.73%) | (14.80%) | (81.01%) | (28.14%) | (108.76%) | (67.99%) |
Free Cash Flow Yield |
— | (1.05%) | (1.05%) | (2.75%) | (11.48%) | (10.22%) | (74.86%) | (38.66%) |
Revenue per Share |
— | 1.89 | 2.41 | 9.23 | 11.38 | 5.17 | 4.38 | 3.07 |
Operating CF per Share |
— | (1.55) | (4.26) | (7.47) | (6.01) | (6.08) | (6.16) | (3.08) |
Capex per Share |
— | (0.77) | (1.81) | (1.66) | (1.25) | (0.75) | (1.19) | (0.13) |
Free Cash Flow per Share |
— | (2.33) | (6.08) | (9.13) | (7.25) | (6.83) | (7.35) | (3.21) |
Cash per Share |
— | 0.00 | 11.95 | 45.59 | 31.35 | 19.42 | 10.82 | 7.62 |
Shareholders Equity per Share |
— | 0.00 | 14.75 | 46.10 | 41.36 | 22.57 | 13.80 | 9.17 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 14.75 | 46.10 | 41.36 | 22.57 | 13.80 | 9.17 |
Free Cash Flow |
— | (66.88) | (193.65) | (310.34) | (304.47) | (331.87) | (381.48) | (178.15) |
Working Capital |
— | — | 353.32 | 1,588.28 | 1,277.12 | 837.89 | 495.48 | 375.87 |
Capital Expenditures |
— | (22.22) | (57.82) | (56.52) | (52.27) | (36.37) | (61.89) | (7.09) |
Net Current Asset Value |
— | 0.00 | 221.44 | 1,219.43 | 647.04 | 433.56 | (58.65) | (139.27) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.41 | 0.75 | 0.18 | 0.11 | 0.14 | 0.27 | 0.04 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.11 | 0.20 | 0.14 | 0.37 | 0.54 | 0.33 |
Cash ROIC |
— | 0.00% | (22.33%) | (9.88%) | (9.98%) | (16.26%) | (29.86%) | (19.13%) |
Accounts Receivable Turnover |
— | 0.00 | 0.88 | 3.97 | 4.37 | 5.01 | 11.26 | 7.29 |
Accounts Payable Turnover |
— | — | 1.42 | 11.75 | 21.91 | 5.46 | 3.79 | 3.80 |
Inventory Turnover |
— | — | 5.20 | 42.54 | 52.86 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | — | 324.83 | 23.05 | 18.68 | 63.01 | 116.09 | 82.10 |
Days of Inventory on Hand |
— | — | 63.97 | 9.46 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | 87.50 | 79.02 | 109.30 | 50.18 | 20.17 | 23.35 |
Average Payables |
— | — | 11.00 | 11.04 | 9.32 | 9.89 | 11.75 | 12.37 |
Average Inventory |
— | — | 3.00 | 3.05 | 3.86 | — | — | — |
Average Assets |
— | 0.00 | 337.58 | 1,373.07 | 2,305.16 | 2,102.33 | 1,521.40 | 1,248.57 |
Average Common Equity |
— | — | 983.00 | 1,018.72 | 1,651.83 | 1,416.71 | 906.60 | 612.32 |
Columns are period end dates